MDA

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Ocean Power Technologies Announces “Merrows”: A Consolidated Solution for Maritime Domain Awareness

Retrieved on: 
Tuesday, April 2, 2024
Control, Machine learning, Cyber, OPT, MDA, Data analysis, Maritime domain awareness, Communication, Computer, PB, Data collection, Command, Collection, Ocean Power Technologies, Artificial intelligence

Merrows will be OPT’s groundbreaking consolidated solution offering comprehensive ocean surveillance.

Key Points: 
  • Merrows will be OPT’s groundbreaking consolidated solution offering comprehensive ocean surveillance.
  • Maritime Domain Awareness represents a complex challenge that encompasses the collection and transmission of data relating to all aspects of, on, under, adjacent to, or bordering on a sea, ocean, or other navigable waterway.
  • Ocean security is national security, and through Merrows, OPT is dedicated to providing the technologies and insights necessary to secure our maritime domains.
  • For more information about Ocean Power Technologies, visit www.OceanPowerTechnologies.com .

Global Electronic Warfare Market Size Expected to Reach $24.76 Billion by 2029

Retrieved on: 
Tuesday, March 26, 2024
Knowledge, CDR, Lockheed, Artificial intelligence, EVO, L3Harris Technologies, Air force, General Dynamics, PCM, USD, Lockheed Martin, Research, NOC, Pratt & Whitney, Partnership, Risk, PALM, Electronics, Radio, The, KULR, F-35, General Dynamics Land Systems, LMT, News, Acquisition, Missile Defense Agency, NGI, Northrop Grumman, Engineering, ICBM, Critical, Element, Growth, MDA, United, Marketing, Grumman, EMD, Jet fuel

The electronic warfare market is marked by the presence of global and local players competing in technology and product offerings; Some major market players are Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, RTX Corporation, and Leonardo S.p.A., amongst others.

Key Points: 
  • The electronic warfare market is marked by the presence of global and local players competing in technology and product offerings; Some major market players are Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, RTX Corporation, and Leonardo S.p.A., amongst others.
  • A report from Mordor Intelligence projected that the Electronic Warfare Market size is estimated at USD 19.30 billion in 2024, and is expected to reach USD 24.76 billion by 2029, growing at a CAGR of 5.11% during the forecast period (2024-2029).
  • Mordor Intelligence concluded: “Various players in the market are investing significantly in research and developing advanced next-generation warfare products having higher electromagnetic capabilities.
  • According to Straits Research , the global electronic warfare market size is estimated to reach an expected value of USD 27.79 billion by 2030, registering a CAGR of 5.8% during the forecast period of 2022 to 2030.

MDA SPACE DEFINES THE NEXT GENERATION OF ROBOTICS WITH NEW MDA SKYMAKER™ PRODUCT LINE

Retrieved on: 
Monday, April 8, 2024
Canadarm, TSX, Robotics, Economics, Space Symposium, MDA, Computer data storage

Unveiled at the Space Symposium conference in Colorado Springs, MDA SKYMAKERTM, the world's leading space robotics technology and services, is now available for all missions and applications.

Key Points: 
  • Unveiled at the Space Symposium conference in Colorado Springs, MDA SKYMAKERTM, the world's leading space robotics technology and services, is now available for all missions and applications.
  • "MDA Space has set the global standard in human-rated space robotics for more than 40 years.
  • Full-service mission operations: Customers can reduce operational costs by having MDA Space perform mission operations from our new state-of-the-art commercial mission control centre, leveraging decades of robotics space mission design and mission operations support.
  • For more information, visit mda.space/skymaker or the MDA Space booth #1327 at Space Symposium.

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.

Burn Boot Camp and Muscular Dystrophy Association Team Up for 8th Annual 'Be Their Muscle' Philanthropic Event

Retrieved on: 
Monday, March 25, 2024
Research, Employment, Entrepreneurship, Skeletal muscle, MDA, ALS, Partnership, Air travel, Education, Duke University Hospital, Social media, Muscular dystrophy, Muscular Dystrophy Association, Senior, Empowerment, Duchenne muscular dystrophy, Duchenne, Clinical trial, FDA, Summer camp, Pharmaceutical industry

Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.

Key Points: 
  • Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.
  • Muscular Dystrophy Association is one of Burn Boot Camp's longest-standing national philanthropic partners," explained Morgan Kline, CEO and Co-Founder of Burn Boot Camp.
  • "Here at the Muscular Dystrophy Association, we stand hand in hand with Burn Boot Camp in our shared commitment to empower communities nationwide.
  • MDA and Burn Boot Camp will be posting throughout the campaign on social media using @MDAorg and @burnbootcamp with #BeTheirMuscle.

Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 21, 2024
HDAC, Gene expression, Cell, Disease, MDA, Associate, Patient, Research, DNA, Public policy, University, Muscular dystrophy, Doctor of Philosophy, Muscular Dystrophy Association, Duchenne muscular dystrophy, Clinical trial, Therapy, Histone deacetylase inhibitor, Stair climbing, Plasma protein binding, FDA, Steroid, DMD, Parent, Lancet, Pediatrics, Human, Food, Pharmaceutical industry

"The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.

Key Points: 
  • "The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.
  • “Muscular Dystrophy Association’s funding was fundamental for the discovery of HDACi in the treatment of Duchenne muscular dystrophy.
  • “We’re excited to celebrate this additional treatment option for people living with Duchenne muscular dystrophy.
  • My son is an example,” said Jessica Curran, MDA family member and mother of Conner who lives with Duchenne muscular dystrophy.

NFL Running Back Nyheim Hines Supports Nation's Largest St. Patrick’s Day Fundraising Campaign to Benefit Muscular Dystrophy Association

Retrieved on: 
Wednesday, March 13, 2024
Cleveland Browns, Nyheim Hines, ALS, MDA, Partnership, Muscular dystrophy, Research, Muscular Dystrophy Association, Family, NFL, Neuromuscular disease

Hines proudly wears the 2024 limited edition MDA Shamrocks t-shirt designed by MDA Board member Matthew Plummer who lives with neuromuscular disease.

Key Points: 
  • Hines proudly wears the 2024 limited edition MDA Shamrocks t-shirt designed by MDA Board member Matthew Plummer who lives with neuromuscular disease.
  • With family members who live or have lived with muscular dystrophy, Hines continues to generate awareness and raise critical funds for the neuromuscular disease community.
  • "It's truly humbling to continue to raise awareness for the neuromuscular disease community through the mission of Muscular Dystrophy Association.
  • It’s our privilege to collaborate with Nyheim to bring the fruits of our mission to his family and millions more across the country."

SatixFy Announces Full Year 2023 Results

Retrieved on: 
Friday, March 29, 2024
Technology, Hardware, Satellite, LEO, Research, European Space Agency, Device, MDA, Application-specific integrated circuit, Cash, Travel, SATX, Insurance, Marketing, Alta Partners, Investment, Research and development, Annual report, RSU, Cryptocurrency

SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.

Key Points: 
  • SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.
  • The decrease in gross profit and margin due to the Company’s engagement in 2023 in projects which carry lower gross margins compared to 2022.
  • Nir Barkan, Acting Chief Executive Officer of SatixFy, commented, “2023 was marked by strategic advancements and solid progress within our product development and customer engagements.
  • “SatixFy is at a key inflection point in the industry, driven in-part by the fast-growing Low Earth Orbit ('LEO') low-latency satellite market providing broad data coverage anywhere, anytime.